If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFocusrite Regulatory News (TUNE)

Share Price Information for Focusrite (TUNE)

Share Price is delayed by 15 minutes
Get Live Data
232.50    -8.50 (-3.53%)
Bid:
230.00
Ask:
235.00
Spread: 5.00 (2.174%)
Market Cap: £136.63m
TUNE Live PriceLast checked at - London Stock Exchange

Intraday Focusrite Share Chart

Issue of Management Shares

18 May 2021 07:00

RNS Number : 9103Y
Focusrite PLC
18 May 2021
 

Strictly embargoed until 07:00 on 18 May 2021

Focusrite plc

("the Company" or "the Group")

Issue of Management Shares

Focusrite plc (AIM: TUNE), the global music and audio products company supplying hardware and software used by professional and amateur musicians and the entertainment industry, is pleased to announce the issue of 13,337 management share awards to the Company's recently appointed Chief Financial Officer, Sally McKone.

The shares, to be issued from the Company's Employee Benefit Trust were determined by the Company's Remuneration Committee and approved by the Board.

The shares will vest in three tranches; the first tranche of 3,176 shares vested in March 2021, the second tranche of 4,029 shares will vest in March 2022 and the third tranche of 6,132 shares will vest in March 2023.

Following the announcement of the Company's interim results, on 13 May 2021 the Company has awarded the first tranche on 17 May 2021 which comprises 3,176 shares. After the Company cash settled the resulting tax and deducted the National Insurance element, Sally McKone will be awarded a net holding of shares in the first tranche resulting in total beneficial holding of 1,683 being 0.003% of the issued ordinary share capital of the Company.

The information set out below is provided in accordance with the requirements of Article 19(3) of the Market Abuse Regulation (EU) No 596/2014.

1

Details of the persons discharging managerial responsibilities person closely associated

a)

Name

Sally McKone

2

Reason for the notification

a)

Position/status

 Chief Financial Officer

b)

Initial notification /Amendment

 Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Focusrite plc

b)

LEI

213800JJ51KA4LOTF736

4A

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument

Ordinary Shares of 0.1p each in Focusrite plc

Identification code

GB00BSBMW716

b)

Nature of the transaction

Issue of shares ordinary shares from EBT of 0.1p each in Focusrite plc.

c)

Price(s) and volume(s)

 

Price(s)

Volumes

Nil cost

3,176 (settled in part by the transfer of 1,683 ordinary shares and in part with a cash payment equal to market value of 1,493 ordinary shares to meet the PDMR's liability to income tax and employee national insurance arising on the issue of 3,176 shares)

 

d)

Aggregated information

- Aggregated volume 

- Price 

Not applicable - single transaction

e)

Date of the transaction

17 May 2021

f)

Place of the transaction

Outside a trading venue

 

 

-ends-

Enquiries:

Focusrite plc: +44 1494 836301

Tim Carroll (CEO)

Sally McKone (CFO)

 

Panmure Gordon (Nominated Adviser and Broker) +44 20 7886 2500

Freddy Crossley / Alina Vaskina

Erik Anderson

 

Belvedere Communications +44 20 3687 2756

John West

Llew Angus

 

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.

 

 

 

Notes to Editors

Focusrite plc is a global music and audio products group that develops and markets proprietary hardware and software products. Used by recording professionals and musicians alike, its solutions facilitate the high-quality production of recorded and live sound. The Focusrite Group trades under six established brands: Focusrite, Focusrite Pro, Novation, Ampify, ADAM Audio and Martin Audio.

With a high-quality reputation and a rich heritage spanning decades, its brands are category leaders in the music-making and audio recording industries. Focusrite and Focusrite Pro offer audio interfaces and other products for recording musicians, producers and professional audio facilities. Novation and Ampify products are used in the creation of electronic music, from synthesisers and grooveboxes to industry-shaping controllers and inspirational music-making apps. ADAM Audio studio monitors have earned a worldwide reputation based on technological innovation in the field of studio loudspeaker technology. Martin Audio designs and manufactures performance-ready systems across the spectrum of sound reinforcement applications. Sequential designs and manufacturers high end analogue synthesizers.

The Focusrite Group has offices in four continents and a global customer base with a distribution network covering approximately 160 territories.

Focusrite plc is traded on the AIM market, London Stock Exchange.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHARMRTMTBBBPB
Date   Source Headline
2nd Jul 20267:01 amRNSDirector Share Dealings
2nd Jul 20267:00 amRNSDirectors' Dealings
30th Jun 202610:26 amRNSDirector/PDMR Shareholding
30th Jun 202610:16 amRNSTR-1
29th Jun 20267:00 amRNSFinal Results
27th May 20267:00 amRNSNotice of Results
5th May 20264:25 pmRNSTR-1
8th Apr 20263:56 pmRNSTR-1
19th Mar 20267:00 amRNSTrading Update: Trading in-line with expectations
2nd Mar 20267:00 amRNSBoard Changes
24th Dec 20259:21 amRNSTR-1
24th Dec 20259:21 amRNSTR-1
24th Dec 20259:19 amRNSTransfer of shares to Trust
24th Dec 20259:19 amRNSTransfer of shares to Trust
18th Nov 202512:38 pmRNSDirector Share Dealings
4th Nov 20257:00 amRNSInterim Results
14th Oct 20257:00 amRNSNotice of Results
16th Sep 20257:00 amRNSTrading Update
7th May 20253:25 pmRNSTR-1
30th Apr 20253:41 pmRNSDividend Timetable Correction
29th Apr 20257:00 amRNSInterim Results
16th Apr 20252:38 pmRNSGrant of Share Options to PDMRs
11th Apr 20258:50 amRNSTR-1
8th Apr 20251:43 pmRNSTR-1
8th Apr 20257:00 amRNSTR-1
8th Apr 20257:00 amRNSTR-1
3rd Apr 20257:00 amRNSNotice of Interim Results
26th Mar 20253:16 pmRNSTR-1
20th Mar 20257:00 amRNSTrading Update
19th Mar 20258:13 amRNSTR-1
4th Mar 20252:46 pmRNSTR-1
31st Jan 202512:29 pmRNSResult of AGM
31st Jan 20257:00 amRNSAGM Statement and Trading Update
11th Dec 20247:00 amRNSTR-1
5th Dec 20243:38 pmRNSDirector Share Dealings
5th Dec 20243:37 pmRNSGrant of Share Options to PDMRs
5th Dec 20247:00 amRNSTR1
27th Nov 20247:00 amRNSFinal Results for the Year Ended 31 Aug 2024
30th Oct 20247:00 amRNSNotice: Final Results, Change of Year End, Auditor
28th Aug 20247:00 amRNSTrading Statement
1st Aug 20247:00 amRNSTR-1
15th Jul 20244:17 pmRNSTR-1
25th Apr 20247:00 amRNSInterim Results
22nd Apr 20246:09 pmRNSTR-1
9th Apr 20247:00 amRNSInvestor Presentation via Investor Meet Company
8th Apr 20247:00 amRNSNotice of Interim Results
22nd Mar 20243:36 pmRNSNotification of PDMR Transactions
22nd Mar 20248:01 amRNSTR-1
20th Mar 20247:01 amRNSTR-1
19th Mar 20244:44 pmRNSNotification of PDMR Transactions

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.